Total Payments
$22,948
2024 Payments
$9,472
Companies
89
Transactions
675
Medicare Patients
14,860
Medicare Billing
$5.2M
Payment Breakdown by Category
Food & Beverage$13,545 (59.0%)
Consulting$8,388 (36.6%)
Education$516.43 (2.3%)
Other$498.50 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,545 | 654 | 59.0% |
| Consulting Fee | $8,388 | 4 | 36.6% |
| Education | $516.43 | 12 | 2.3% |
| Long term medical supply or device loan | $498.50 | 5 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TriSalus Life Sciences, Inc. | $7,013 | 3 | $0 (2024) |
| Seagen Inc. | $1,889 | 26 | $0 (2023) |
| Genentech USA, Inc. | $1,501 | 100 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,365 | 69 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,314 | 57 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $710.21 | 26 | $0 (2024) |
| Lilly USA, LLC | $682.74 | 21 | $0 (2024) |
| PFIZER INC. | $606.35 | 41 | $0 (2024) |
| Janssen Biotech, Inc. | $569.78 | 23 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $484.69 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,472 | 109 | TriSalus Life Sciences, Inc. ($7,013) |
| 2023 | $2,607 | 119 | Novartis Pharmaceuticals Corporation ($428.61) |
| 2022 | $1,878 | 80 | Novartis Pharmaceuticals Corporation ($273.10) |
| 2021 | $1,419 | 71 | Merck Sharp & Dohme Corporation ($201.27) |
| 2020 | $2,121 | 38 | Seagen Inc. ($1,548) |
| 2019 | $1,878 | 99 | Merck Sharp & Dohme Corporation ($339.76) |
| 2018 | $1,794 | 81 | AstraZeneca Pharmaceuticals LP ($222.76) |
| 2017 | $1,779 | 78 | Lilly USA, LLC ($222.11) |
All Payment Transactions
675 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $34.85 | General |
| Category: BioOncology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $29.17 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.36 | General |
| 11/15/2024 | TriSalus Life Sciences, Inc. | TRINAV INFUSION SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Epizyme, Inc. | Onivyde (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Immunology | ||||||
| 10/18/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $10.26 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: BioOncology | ||||||
| 10/15/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/14/2024 | TriSalus Life Sciences, Inc. | TRINAV INFUSION SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Genentech USA, Inc. | Tecentriq (Biological), Tecentriq Hybreza | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: BioOncology | ||||||
| 10/04/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $34.44 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/03/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: HEMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 60 | 3,616 | 112,072 | $2.9M | $1.0M |
| 2022 | 63 | 3,659 | 86,109 | $3.1M | $1.2M |
| 2021 | 63 | 3,893 | 95,670 | $4.1M | $1.6M |
| 2020 | 66 | 3,692 | 76,772 | $3.7M | $1.4M |
Total Patients
14,860
Total Services
370,623
Medicare Billing
$5.2M
Procedure Codes
252
All Medicare Procedures & Services
252 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 12,404 | $1.1M | $535,934 | 48.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 177 | 673 | $225,329 | $94,189 | 41.8% |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | Office | 2023 | 36 | 11,900 | $124,950 | $67,964 | 54.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 333 | 592 | $171,539 | $54,770 | 31.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 24 | 18,100 | $167,787 | $41,642 | 24.8% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 16 | 360 | $93,661 | $34,846 | 37.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 79 | 322 | $156,800 | $34,085 | 21.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 28 | 37,500 | $93,750 | $32,068 | 34.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 22 | 10,270 | $44,880 | $13,800 | 30.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 419 | 1,308 | $84,967 | $13,438 | 15.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 504 | 1,664 | $91,474 | $12,521 | 13.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 72 | 80 | $34,094 | $11,589 | 34.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 164 | $26,771 | $10,801 | 40.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 62 | 163 | $37,490 | $8,497 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $20,790 | $7,651 | 36.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 59 | 315 | $42,322 | $7,047 | 16.7% |
| 96416 | Administration of prolonged chemotherapy into vein | Office | 2023 | 14 | 54 | $27,339 | $5,760 | 21.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 104 | 430 | $29,240 | $4,955 | 16.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 49 | $12,740 | $4,872 | 38.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 79 | $13,904 | $4,771 | 34.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 30 | 92 | $22,908 | $4,604 | 20.1% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 69 | 459 | $18,360 | $4,114 | 22.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 165 | 276 | $20,562 | $3,674 | 17.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 84 | 184 | $17,112 | $3,029 | 17.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 15 | 53 | $11,089 | $2,444 | 22.0% |
About Dr. Gary Gordon, M.D
Dr. Gary Gordon, M.D is a Hematology & Oncology healthcare provider based in Elk Grove Village, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245291780.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Gordon, M.D has received a total of $22,948 in payments from pharmaceutical and medical device companies, with $9,472 received in 2024. These payments were reported across 675 transactions from 89 companies. The most common payment nature is "Food and Beverage" ($13,545).
As a Medicare-enrolled provider, Gordon has provided services to 14,860 Medicare beneficiaries, totaling 370,623 services with total Medicare billing of $5.2M. Data is available for 4 years (2020–2023), covering 252 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Elk Grove Village, IL
- Active Since 03/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1245291780
Products in Payments
- TRINAV INFUSION SYSTEM (Device) $7,013
- ADCETRIS (Biological) $1,731
- KEYTRUDA (Biological) $1,265
- KISQALI (Drug) $427.39
- Kadcyla (Biological) $405.60
- IMBRUVICA (Drug) $403.12
- DARZALEX (Biological) $328.51
- Alecensa (Biological) $319.93
- LYNPARZA (Drug) $290.43
- JAKAFI (Drug) $246.61
- XARELTO (Drug) $241.22
- IMFINZI (Drug) $219.26
- Kick, Airo, Curve, Buzz, Node, Exact Trac, Novalis, TramaCad, Elements (Device) $219.09
- TECENTRIQ (Biological) $218.47
- CYRAMZA (Drug) $217.60
- Lenvima (Drug) $202.42
- Cabometyx (Drug) $201.82
- VERZENIO (Drug) $194.74
- BOSULIF (Drug) $174.61
- OPDIVO (Biological) $172.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Elk Grove Village
Dr. Gary Kay, M.d, M.D
Hematology & Oncology — Payments: $516,983
Hematology & Oncology $516,983
Dr. Gary Grad, M.d, M.D
Hematology & Oncology — Payments: $338,552
Hematology & Oncology $338,552
Dr. Alkarim Tajuddin, M.d, M.D
Hematology & Oncology — Payments: $44,272
Hematology & Oncology $44,272
Dr. Bruce Bank, M.d, M.D
Hematology & Oncology — Payments: $34,272
Hematology & Oncology $34,272
Dr. Ronald Shade, M.d, M.D
Hematology & Oncology — Payments: $32,380
Hematology & Oncology $32,380
Dr. Steven Kanter, M.d, M.D
Hematology & Oncology — Payments: $24,270
Hematology & Oncology $24,270